• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coverage

Latest content

Antti Siltanen

Analyst

Antti Siltanen portrait

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsNightingale HealthBioretecAiforia TechnologiesBiohitOrionModulight

Latest content

ShowingAll content types

Herantis H1'26: Phase 2 preparation is progressing

Research 21.08.2026 klo 10.08 by Antti Siltanen
Herantis Pharma

Biohit: GastroPanel Quick Test also works during proton pump inhibitor therapy

Analyst Comment 19.08.2026 klo 09.27 by Antti Siltanen
Biohit

Nightingale's remote tests to be included in Supernormal's weight loss service

Analyst Comment 19.08.2026 klo 10.12 by Antti Siltanen
Nightingale Health

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account

Modulight Q2'26 preview: Savings measures likely to improve earnings while revenue declines

Analyst Comment 19.08.2026 klo 10.22 by Antti Siltanen
Modulight

Herantis H1'26 preview: Focus on Phase IIa preparations and funding

Analyst Comment 18.08.2026 klo 09.01 by Antti Siltanen
Herantis Pharma

New partnership for Nightingale in the UK

Analyst Comment 18.08.2026 klo 10.18 by Antti Siltanen
Nightingale Health

Nexstim H1'26: Brainlab potential to be weighed later this year

Research 17.08.2026 klo 10.09 by Antti Siltanen
Nexstim

Bioretec Q2'26: There is growth, but the trend is not yet clear

Research 14.08.2026 klo 11.03 by Antti Siltanen
Bioretec

Bioretec H1'26: Expansion of the product portfolio into spinal applications progresses

Video 13.08.2026 klo 14.16 by Antti Siltanen
Bioretec

Nexstim H1'26 preview: Our expectations for the beginning of the year are moderate

Analyst Comment 11.08.2026 klo 09.25 by Antti Siltanen
Nexstim